FDA approves Almirall's Klisyri® (tirbanibulin) for enlarged actinic keratosis treatment on the face or scalp up to 100 cm².
FDA approves Almirall's Klisyri® (tirbanibulin) for enlarged actinic keratosis treatment on the face or scalp up to 100 cm². The 5-day topical treatment increases treatment flexibility, with a Phase 3 study showing consistent results regarding skin reactions and adverse events. The expanded approval allows for four times the surface area compared to previous limitations.
June 10, 2024
4 Articles